Condition: Obesity/Overweight · Sponsor: Altimmune, Inc.
This study will evaluate the efficacy and safety of ALT-801 once-weekly versus placebo as an adjunct to a reduced-calorie diet and increased physical activity in patients with obesity/overweight.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Altimmune CTM | Birmingham, Alabama, United States | — |
| Altimmune CTM | Mesa, Arizona, United States | — |
| Altimmune CTM | Los Angeles, California, United States | — |
| National Research Institute | Los Angeles, California, United States | — |
| Altimmune CTM | Montclair, California, United States | — |
| Altimmune CTM | Santa Barbara, California, United States | — |
| Altimmune CTM | Boca Raton, Florida, United States | — |
| Altimmune CTM | Clearwater, Florida, United States | — |
| Altimmune CTM | Fort Myers, Florida, United States | — |
| Altimmune CTM | Jacksonville, Florida, United States | — |
| Altimmune CTM | Port Orange, Florida, United States | — |
| Altimmune CTM | Sunrise, Florida, United States | — |
+ 19 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05295875